Definitive Contract 75N93024C00017
Award Date 9/1/24
Potential Completion Date 8/31/27
Potential Value $3M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
CRYSTAL CITY, CA 90220, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $3,599,784.00 Firm Fixed Price contract to Molecular Express, Inc., a minority-owned, self-certified small disadvantaged business, for the DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151. This definitive contract does not have a set-aside designation and is scheduled for completion by September 29, 2028. Molecular Express, Inc. specializes in developing innovative drug formulations, therapeutics, and...
- This is a $1,999,866.00 Firm Fixed Price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Molecular Express, Inc. for the design and engineering of Vesivax HIV immunogen formulations. The contract is a Total Small Business set-aside as part of the Small Business Innovation Research (SBIR) Program Phase II. Molecular Express is a minority-owned, self-certified small disadvantaged business...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Molecular Express, Inc., a minority-owned small business. The $296,286 fixed-price contract is for the development of self-replicating HIV vaccines using in vitro reconstituted virus-like particles. Molecular Express has previously worked on other infectious disease treatment and vaccine...
- This award is for a Small Business Innovation Research (SBIR) contract with the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID), valued at $213,800. The contract was awarded to Molecular Express, Inc., a minority-owned small business focused on developing biomedical research and treatments for infectious diseases. The contract was awarded under SBIR Topic 061, "Mucosal Stimulatory Vesivax Vaccines Against Enteric Infections," with a...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Molecular Express, Inc., a minority-owned small disadvantaged business. The contract, valued at $440,933.00, is a Small Business Innovation Research (SBIR) Program Phase I award under TOPIC 039 VACCINES AGAINST PATHOGENS WITH SMALL MARKET POTENTIAL. The purpose of the contract is the SELECTION OF VESIVAX VACCINE FOR WEST NILE...
- This is a $599,983 firm fixed-price contract awarded by the Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases to Molecular Express, Inc., a minority-owned small business, under the Small Business Innovation Research (SBIR) program. The objective of the contract is to develop an effective HIV vaccine by exploring co-delivery formulations of HIV antigens and adjuvants. This contract is part of the agency's "Evaluation...
- Molecular Express Inc. was awarded a $2.3 million definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to evaluate different co-delivery methods of a model HIV antigen using the Vesivax liposomal platform. This contract was awarded under a Small Business Innovation Research solicitation issued jointly by NIH and the Centers for Disease Control and Prevention seeking proposals aligned with agency missions through innovative solutions...
- This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,993, was awarded to Molecular Express Inc. to develop a Vesivax platform-based liposomal formulation that will efficiently display the HIV immunogen. The solicitation sought proposals to conduct research and development in support of NIH and CDC agency missions, including alternatives to cell culture materials, cancer immunotherapy manufacturing, and...
- This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,961, was awarded to Molecular Express Inc. to identify a potential HIV antigen-conjugated vaccine formulation. The contractor will explore co-delivery of HIV antigens and adjuvant molecules, as requested in the NIH/CDC SBIR solicitation seeking proposals on alternatives to cell culture materials, various cancer-related technologies, opioid withdrawal...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $600,000 firm-fixed-price definitive contract to Integral Molecular Inc., a small business biotechnology company, for "ADJUVANT TARGET DISCOVERY FOR VACCINES AND FOR AUTOIMMUNE AND ALLERGIC DISEASES." The contract has a completion date of June 29, 2024. Integral Molecular specializes in membrane protein research and has received numerous federal contracts and grants from agencies like the National Institutes of...